Insulinoma classification: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) (Created page with "__NOTOC__ {{Insulinoma}} {{CMG}}; {{AE}} ==Overview== *There is no established system for the classification of [disease name]. OR *[Disease name] may be classified accordin...") |
|||
| Line 24: | Line 24: | ||
*There is no established system for the classification of [disease name]. | *There is no established system for the classification of [disease name]. | ||
OR | OR | ||
* | *Insulinoma may be classified according to malignant potential into 2 subtypes/groups: | ||
** | **Benign | ||
** | **Malignant<br> | ||
90% of Insulinoma are benign in nature while 10% has malignant potential to invade adjacent soft tissues or structures | |||
OR | OR | ||
* | * Previously Insulinoma was classified into 2 subtypes based on Radioimmunoassay<ref name="pmid6311653">{{cite journal| author=Berger M, Bordi C, Cüppers HJ, Berchtold P, Gries FA, Münterfering H et al.| title=Functional and morphologic characterization of human insulinomas. | journal=Diabetes | year= 1983 | volume= 32 | issue= 10 | pages= 921-31 | pmid=6311653 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6311653 }} </ref>: | ||
** | **Group A | ||
** | **Group B | ||
**[classification method 3] | **[classification method 3] | ||
*[Disease name] may be classified into several subtypes based on: | *[Disease name] may be classified into several subtypes based on: | ||
Revision as of 21:12, 9 August 2017
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma classification On the Web |
|
American Roentgen Ray Society Images of Insulinoma classification |
|
Risk calculators and risk factors for Insulinoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
- There is no established system for the classification of [disease name].
OR
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
- [Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3].
- [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
- Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
- If the staging system involves specific and characteristic findings and features:
- According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
- The staging of [malignancy name] is based on the [staging system].
OR
- There is no established system for the staging of [malignancy name].
Classification
- There is no established system for the classification of [disease name].
OR
- Insulinoma may be classified according to malignant potential into 2 subtypes/groups:
- Benign
- Malignant
90% of Insulinoma are benign in nature while 10% has malignant potential to invade adjacent soft tissues or structures OR
- Previously Insulinoma was classified into 2 subtypes based on Radioimmunoassay[1]:
- Group A
- Group B
- [classification method 3]
- [Disease name] may be classified into several subtypes based on:
- [classification method 1]
- [classification method 2]
- [classification method 3]
OR
- Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
- If the staging system involves specific and characteristic findings and features:
- According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
- The staging of [malignancy name] is based on the [staging system].
OR
- There is no established system for the staging of [malignancy name].
References
- ↑ Berger M, Bordi C, Cüppers HJ, Berchtold P, Gries FA, Münterfering H; et al. (1983). "Functional and morphologic characterization of human insulinomas". Diabetes. 32 (10): 921–31. PMID 6311653.